Skip to main content
Cybin Inc. logo

Cybin Inc. — Investor Relations & Filings

Ticker · HELP NEO Manufacturing
Open in API
Filings indexed 441 across all filing types
Latest filing 2025-01-09 Regulatory Filings
Country CA Canada
Listing NEO HELP

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Cybin’s CEO will participate in an upcoming investor healthcare summit and provides webcast details. It contains no substantive financial results, slides, or report attachments, and is not a formal presentation deck or earnings release. It does not fit specialized categories such as ER, IP, 10-K, DIV, etc. Therefore, it falls into the fallback category for miscellaneous regulatory/press announcements: Regulatory Filings (RNS).
2025-01-09 English
Decision Document (Third Amendment to Final).pdf
Capital/Financing Update Classification · 1% confidence The document is an official receipt from the Ontario Securities Commission for Amendment No. 3 to Cybin Inc.’s Short Form Base Shelf Prospectus (NI 44-102). A shelf prospectus amendment directly relates to the company’s capacity to raise capital and alter its financing arrangements. This is not a full financial report, management announcement, or delisting notice, but a regulatory notice confirming a financing-related filing. Therefore, it falls under the Capital/Financing Update category (CAP).
2025-01-07 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Business Wire press release announcing poster presentations at a scientific conference, summarizing clinical data and forward-looking statements. It is not an earnings release, financial report, regulatory notice, or shareholder report, nor does it fit any specific M&A, board change, or capital markets category. This falls into the fallback category for miscellaneous corporate announcements.
2024-12-10 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that Cybin’s CEO and CMO will participate in a Water Tower Research fireside chat, with details on topics and registration. It does not present financial results, call transcripts, capital changes, governance documents, or other report types. As a general announcement to investors and the market that doesn’t fit a more specific category, it is best classified as a Regulatory Filing (RNS).
2024-12-04 English
News release - English.pdf
Regulatory Filings
2024-11-18 English
News release - English.pdf
Regulatory Filings
2024-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.